John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 40 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 112 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.

John M. Sprague, the Chief Financial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 40 shares of common stock. The transaction, classified under the code 'M', indicates an exercise or conversion of derivative security. Following this transaction, Sprague's direct holdings in the company increased to a total of 112 shares of common stock. The action reflects a continued investment by the CFO in the company, signaling potential confidence in T2 Biosystems' future performance.